Okamoto, Kiyoshi
Eisai (Japan)
3 papers on CoChatORCID 0000-0001-8989-4060
Most cited papers
- Verified
Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014) · Journal of Thyroid Research
Thyroid Cancer Diagnosis and TreatmentAngiogenesis and VEGF in Cancer
Cited by 475
- Verified
Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J. (2015) · ACS Medicinal Chemistry Letters
Angiogenesis and VEGF in CancerEnzyme Structure and Function
Cited by 285
- Verified
Abstract 3266: Antitumor activity of a combination of lenvatinib mesilate, ifosfamide, and etoposide against human pediatric osteosarcoma cell lines
Matsuki, M., Okamoto, K., Dezso, Z., Agoulnik, S. I., Funahashi, Y., & Matsui, J. (2016) · Cancer Research
Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments
Cited by 2
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free